Nebenwirkungen · Tracleer
Tracleer 32 mg dispersible tablets · Abschnitt 4.8 · PDF-Seite 36
HOS-110012 · Präparat HOS-093279
In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases 3 ULN were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients. Elevations to 8 ULN were seen in 3.6% of the bosentan-treated patients and 0.4% of the placebo-treated patients. Elevations in aminotransferases were associated with elevated bilirubin ( 2 ULN) without evidence of biliary obstruction in 0.2% (5 patients) on bosentan and 0.3% (6 patients) on placebo.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-10-25T15:01:00Z · SHA-256 eddfcd40df26bd01c2c7847da53c544c94e0bafb8bcc62374b5c7788669470bc · Passage 017d746564736296bf120a13a38e7e05627aa899a1e3f4f39c70803079473249 · Zeichen 8783–9296 im Abschnitt